Comparison of the Multiattribute Utility Instruments EQ-5D and SF-6D in a Europe-Wide Population-Based Cohort of Patients with Inflammatory Bowel Disease 10 Years after Diagnosis
Table 5
EQ-5D and SF-6D index scores and subjectively perceived disease activities stratified by countries.
Current symptoms
Flares in the previous year
Yes
No
Yes
No
EQ5D scores Mean (95% CI)
Italy
0.76 (0.69–0.84)
0.9 (0.87–0.94)
0.78 (0.70–0.86)
0.89 (0.86–0.93)
Greece
0.53 (0.25–0.82)
0.83 (0.77–0.88)
0.57 (0.16–0.98)
0.81 (0.75–0.87)
Israel
0.64 (0.50–0.77)
0.88 (0.76–0.99)
0.73 (0.37–1)
0.79 (0.69–0.88)
Denmark
0.67 (0.58–0.76)
0.89 (0.84–0.95)
0.75 (0.64–0.87)
0.83 (0.78–0.89)
Norway
0.66 (0.59–0.72)
0.88 (0.85–0.90)
0.70 (0.63–0.79)
0.80 (0.76–0.84)
Netherlands
0.69 (0.64–075)
0.85 (0.81–090)
0.74 (0.62–0.85)
0.79 (0.76–0.83)
Spain
0.83 (0.76–0.90)
0.92 (0.86–0.97)
0.89 (0.82–0.95)
0.88 (0.83–0.94)
SF6D scores Mean (95% CI)
Italy
0.69 (0.64–0.75)
0.83 (0.81–0.85)
0.78 (0.70–0.86)
0.81 (0.79–0.84)
Greece
0.62 (0.46–0.77)
0.80 (0.77–0.84)
0.67 (0.36–0.97)
0.79 (0.76–0.83)
Israel
0.61 (0.56–0.65)
0.64 (0.61–0.67)
0.57 (0.49–0.65)
0.63 (0.61–0.66)
Denmark
0.74 (0.70–0.79)
0.84 (0.81–0.87)
0.77 (0.72–0.82)
0.81 (0.78–0.84)
Norway
0.71 (0.68–0.74)
0.82 (0.80–0.84)
0.73 (0.69–0.77)
0.79 (0.77–0.81)
Netherlands
0.70 (0.69–0.73)
0.80 (0.77–0.83)
0.71 (0.64–0.79)
0.76 (0.74–0.79)
Spain
0.75 (0.71–0.79)
0.84 (0.86–0.97)
0.79 (0.74–0.85)
0.81 (0.78–0.84)
Mean (95% confidence interval) utility indices with and without symptoms/flares in the previous year; significance of the differences between symptoms/no symptoms and flares/no flares: , , and (-test and Mann-Whitney test).
